---
input_text: "Developing an Implementation Blueprint for the NIH HEAL Initiative GRACE
  Trial: Perspectives on Acupuncture and Guided Relaxation for Chronic Sickle Cell
  Disease Pain. Objective: This study aimed to explore perspectives of people living
  with sickle cell disease (SCD) and SCD clinic providers and staff about the use
  of acupuncture and guided relaxation for treating chronic SCD pain. Data obtained
  were to inform an implementation blueprint for an effectiveness implementation clinical
  trial (GRACE Trial) testing whether acupuncture or guided relaxation reduces chronic
  pain when compared with usual care. Design: Qualitative research design. Methods:
  We conducted 33 semistructured interviews with people with SCD and SCD clinic providers
  and staff. Interviews were transcribed and coded. A deductive content analysis process
  was used to identify themes. Results: Four themes were identified: Receptivity to
  Acupuncture and Guided Relaxation, Limited Awareness, Complementary and Integrative
  Health (CIH) Therapy Preference, and Access Barriers. Both patients and clinic providers
  and staff were open to the use of acupuncture and guided relaxation for chronic
  pain treatment. After learning about these CIH therapies, some patients expressed
  a preference for one therapy over the other. They also discussed their ability to
  successfully engage with each therapy. There is a need to dispel misconceptions
  about the therapies by increasing understanding of how each therapy is implemented
  and functions to reduce pain. We identified several potential barriers that might
  affect the success of the trial and future health system integration, including
  time, transportation, and technology. Conclusion: This study is one of the first
  to present perspectives of both patients with SCD and clinic providers and staff
  on the use of acupuncture and guided relaxation for chronic SCD pain. Stakeholders'
  early input and perspectives highlighted that they welcome nonpharmacological CIH
  therapies. Implementation of a clinical trial and future health system integration
  will require the addressing misinformation and identifying strategies to overcome
  access barriers. ClinicalTrials.gov Identifier: NCT04906447."
raw_completion_output: |-
  primary_disease: Sickle Cell Disease (SCD)

  medical_actions: Acupuncture; Guided Relaxation; Increasing understanding of therapies; Addressing misinformation; Identifying strategies to overcome access barriers

  symptoms: Chronic SCD pain

  chemicals: 

  action_annotation_relationships: Acupuncture TREATS Chronic SCD pain IN Sickle Cell Disease (SCD); Guided Relaxation TREATS Chronic SCD pain IN Sickle Cell Disease (SCD); Increasing understanding of therapies PREVENTS misconceptions IN Sickle Cell Disease (SCD); Addressing misinformation PREVENTS misconceptions IN Sickle Cell Disease (SCD); Identifying strategies to overcome access barriers PREVENTS barriers to treatment IN Sickle Cell Disease (SCD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Identifying strategies to overcome access barriers PREVENTS barriers to treatment IN Sickle Cell Disease (SCD)

  ===

extracted_object:
  primary_disease: MONDO:0007374
  medical_actions:
    - Acupuncture
    - Guided Relaxation
    - Increasing understanding of therapies
    - Addressing misinformation
    - Identifying strategies to overcome access barriers
  symptoms:
    - Chronic SCD pain
  action_annotation_relationships:
    - subject: <Acupuncture>
      predicate: <TREATS>
      object: <Chronic SCD pain>
      qualifier: MONDO:0007374
      subject_qualifier: <None>
      object_qualifier: <None>
      subject_extension: <None>
      object_extension: <None>
    - subject: Guided Relaxation
      predicate: TREATS
      object: Chronic SCD pain
      qualifier: MONDO:0007374
    - subject: <Increasing understanding of therapies>
      predicate: <PREVENTS>
      object: <misconceptions>
      qualifier: MONDO:0007374
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <therapies>
      object_extension: <misconceptions>
    - subject: <Addressing misinformation>
      predicate: <PREVENTS>
      object: <misconceptions>
      qualifier: MONDO:0007374
      subject_qualifier: <Not applicable>
      object_qualifier: <Not applicable>
      subject_extension: <Not applicable>
      object_extension: <Not applicable>
    - subject: Identifying strategies to overcome access barriers
      predicate: PREVENTS
      object: barriers to treatment
      qualifier: MONDO:0007374
named_entities:
  - id: MONDO:0011382
    label: sickle cell disease
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:81579
    label: erythropoietin
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001001
    label: Gene therapy
  - id: CHEBI:35480
    label: analgesics
  - id: CHEBI:33281
    label: antibiotics
  - id: MAXO:0001077
    label: Splenectomy
  - id: MAXO:0000756
    label: Blood transfusion
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: HP:0001297
    label: Stroke
  - id: HP:0002863
    label: Myelodysplastic syndrome
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:82594
    label: Ferritin
  - id: MONDO:0000984
    label: thalassemia
  - id: MONDO:0018881
    label: myelodysplastic syndrome
  - id: HP:0002140
    label: Ischemic Stroke
  - id: MONDO:0005380
    label: avascular necrosis
  - id: MAXO:0009047
    label: total hip replacement
  - id: HP:0010885
    label: avascular necrosis
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:41879
    label: dexamethasone
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:125354
    label: plerixafor
  - id: CHEBI:9168
    label: sirolimus
  - id: CHEBI:8764
    label: mycophenolate mofetil
  - id: HP:0012531
    label: Pain
  - id: MAXO:0000515
    label: Extracorporeal life support
  - id: HP:0001708
    label: Right ventricular failure
  - id: HP:0033515
    label: opioid dependence
  - id: MONDO:0005632
    label: Acute chest syndrome in sickle cell disease
  - id: HP:0001945
    label: fever
  - id: HP:0001878
    label: Hemolytic anemia
  - id: CHEBI:6121
    label: ketamine
  - id: CHEBI:17303
    label: morphine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0031274
    label: hypovolemic shock
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: arginine
  - id: CHEBI:18211
    label: citrulline
  - id: CHEBI:3638
    label: chloroquine
  - id: CHEBI:50733
    label: nutritional supplements
  - id: MONDO:0005570
    label: Blood disorders
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0100626
    label: end-stage liver disease
  - id: MONDO:0016363
    label: Iron overload diseases
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0010203
    label: echocardiography
  - id: HP:0002870
    label: obstructive sleep apnoea (OSA)
  - id: HP:0000520
    label: Proptosis
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000058
    label: pharmacological treatment
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: HP:0002878
    label: Acute respiratory failure
  - id: HP:0012594
    label: Microalbuminuria
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: CHEBI:35457
    label: angiotensin-converting enzyme inhibitor
  - id: MAXO:0000652
    label: angiotensin-converting enzyme inhibitor therapy
  - id: HP:0000112
    label: kidney disease
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0000827
    label: serum ferritin measurement
  - id: HP:0001875
    label: neutropenia
  - id: CHEBI:4356
    label: <desferrioxamine (DFO)
  - id: CHEBI:17941
    label: deferiprone (DFP)
  - id: CHEBI:49005
    label: deferasirox (DFX)
  - id: CHEBI:38157
    label: iron chelators
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:9144
    label: silymarin
  - id: MAXO:0000750
    label: conditioning regimens (fludarabine-thiotepa-treosulfan, busulfan-cyclophosphamide)
  - id: CHEBI:82557
    label: treosulfan
  - id: HP:0100602
    label: preeclampsia
  - id: HP:0001622
    label: preterm delivery
  - id: HP:0001511
    label: intrauterine growth restriction
  - id: CHEBI:50858
    label: corticosteroids
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0100639
    label: erectile dysfunction
  - id: CHEBI:71940
    label: Tadalafil
  - id: CHEBI:71942
    label: PDE5 inhibitors
  - id: MONDO:0019740
    label: Acquired thrombotic thrombocytopenic purpura (aTTP)
  - id: CHEBI:24261
    label: Glucocorticoids
  - id: MAXO:0000194
    label: Opioid therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:35705
    label: immunosuppressive agents
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002027
    label: Abdominal pain
  - id: HP:0002315
    label: Headache
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:28876
    label: Melphalan
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:44185
    label: Methotrexate
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:47381
    label: Diclofenac
  - id: HP:0000832
    label: Primary hypothyroidism
  - id: HP:0011787
    label: Central hypothyroidism
  - id: CHEBI:18248
    label: Iron
  - id: CHEBI:30660
    label: Thyroxine
  - id: HP:0001342
    label: Hemorrhagic strokes
  - id: HP:0002326
    label: Transient ischemic attack
  - id: MONDO:0044033
    label: Posterior reversible encephalopathy syndrome
